AU2019242381B2 - CAR-Treg-based therapies for treating neurodegenerative diseases - Google Patents

CAR-Treg-based therapies for treating neurodegenerative diseases Download PDF

Info

Publication number
AU2019242381B2
AU2019242381B2 AU2019242381A AU2019242381A AU2019242381B2 AU 2019242381 B2 AU2019242381 B2 AU 2019242381B2 AU 2019242381 A AU2019242381 A AU 2019242381A AU 2019242381 A AU2019242381 A AU 2019242381A AU 2019242381 B2 AU2019242381 B2 AU 2019242381B2
Authority
AU
Australia
Prior art keywords
seq
disease
composition
cells
tregs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019242381A
Other languages
English (en)
Other versions
AU2019242381A1 (en
Inventor
Philip G. Ashton-Rickardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aztherapies Inc
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of AU2019242381A1 publication Critical patent/AU2019242381A1/en
Assigned to AZTHERAPIES, INC. reassignment AZTHERAPIES, INC. Request for Assignment Assignors: SMITH THERAPEUTICS INC.
Application granted granted Critical
Publication of AU2019242381B2 publication Critical patent/AU2019242381B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2019242381A 2018-03-27 2019-03-21 CAR-Treg-based therapies for treating neurodegenerative diseases Active AU2019242381B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648684P 2018-03-27 2018-03-27
US62/648,684 2018-03-27
PCT/US2019/023395 WO2019190879A1 (en) 2018-03-27 2019-03-21 Car-treg-based therapies for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU2019242381A1 AU2019242381A1 (en) 2020-11-19
AU2019242381B2 true AU2019242381B2 (en) 2025-04-24

Family

ID=68060734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019242381A Active AU2019242381B2 (en) 2018-03-27 2019-03-21 CAR-Treg-based therapies for treating neurodegenerative diseases

Country Status (8)

Country Link
US (2) US12173030B2 (enExample)
EP (1) EP3773629A4 (enExample)
JP (3) JP2021531280A (enExample)
KR (2) KR102892999B1 (enExample)
CN (1) CN112867496A (enExample)
AU (1) AU2019242381B2 (enExample)
CA (1) CA3095298A1 (enExample)
WO (1) WO2019190879A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102892999B1 (ko) 2018-03-27 2025-11-28 아즈테라피즈 인코포레이티드 신경변성 질환을 치료하기 위한 CAR-Treg-기반 요법
CN116134144A (zh) 2020-04-23 2023-05-16 Az治疗股份有限公司 细胞的hla-i类mhc消融
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
CN117957246A (zh) * 2021-09-03 2024-04-30 桑格摩生物治疗股份有限公司 Mog结合蛋白和其用途
WO2023047098A2 (en) * 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-p75ntr chimeric antigen receptor
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
EP2046828A2 (en) 2006-07-07 2009-04-15 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
SG10201602159VA (en) * 2011-02-11 2016-04-28 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
KR20140071277A (ko) * 2011-05-19 2014-06-11 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
ES3051035T3 (en) 2014-12-30 2025-12-23 The Brigham And Womens Hospital Inc Methods to improve cell therapy
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
MX393951B (es) * 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
CN111357090B (zh) * 2017-11-11 2024-01-05 微材料有限责任公司 用于高压处理腔室的气体输送系统
KR102892999B1 (ko) 2018-03-27 2025-11-28 아즈테라피즈 인코포레이티드 신경변성 질환을 치료하기 위한 CAR-Treg-기반 요법
US20230210899A1 (en) 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOA FRANSSON ET AL: JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. 1, 30 May 2012 (2012-05-30), pages 112, XP021127207, ISSN: 1742-2094, DOI: 10.1186/1742-2094-9-112 *

Also Published As

Publication number Publication date
US20210023137A1 (en) 2021-01-28
JP2025123315A (ja) 2025-08-22
WO2019190879A1 (en) 2019-10-03
CN112867496A (zh) 2021-05-28
CA3095298A1 (en) 2019-10-03
EP3773629A1 (en) 2021-02-17
AU2019242381A1 (en) 2020-11-19
KR102892999B1 (ko) 2025-11-28
US20250129158A1 (en) 2025-04-24
JP2024086870A (ja) 2024-06-28
KR20250174989A (ko) 2025-12-15
JP7697096B2 (ja) 2025-06-23
KR20210135921A (ko) 2021-11-16
US12173030B2 (en) 2024-12-24
JP2021531280A (ja) 2021-11-18
EP3773629A4 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
AU2019242381B2 (en) CAR-Treg-based therapies for treating neurodegenerative diseases
EP3411065B1 (en) Clec9a binding agents
US8389016B2 (en) Use of a CD28 binding substance for making a pharmaceutical composition
JP5597553B2 (ja) 疾患治療剤
EP2771031B1 (en) Humanized antibodies that recognize alpha-synuclein
Manjunatha et al. Multiple sclerosis: therapeutic strategies on the horizon
JP2017081926A (ja) Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用
US20150086575A1 (en) B cell surface reactive antibodies
CN115175935A (zh) Cal-t构建体及其用途
TWI717848B (zh) 抗體於治療神經退化性疾病的用途
JP2018504400A (ja) Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US20230210899A1 (en) CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
JP2023501211A (ja) 逐次抗ｃｄ１９治療
Warrington et al. Method of identifying natural antibodies for remyelination
US20210214429A1 (en) Antibodies for the treatment of synucleinopathies and neuroinflammation
US20190328781A1 (en) Manufacturing methods for cell-based therapeutic compositions
CN116942831A (zh) Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
US20170198026A1 (en) Compositions And Methods For Treating Tumors And Immune Based Inflammatory Diseases
WO2025253079A1 (fr) Anticorps monoclonal d'isotype igm anti-hla-dr potentialisant l'activite d'anticorps d'isotype igg1 ou igm anti-cd20
EP0839195A1 (fr) Sequences nucleotidiques et peptidiques pour le traitement de la myasthenie
HK1201450B (en) Humanized antibodies that recognize alpha-synuclein

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AZTHERAPIES, INC.

Free format text: FORMER APPLICANT(S): SMITH THERAPEUTICS INC.

FGA Letters patent sealed or granted (standard patent)